BLAINJECTIONINJECTABLEPriority Review
Approved
Jun 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
VYVGART HYTRULO (efgartigimod alfa and hyaluronidase (human recombinant)) by argenx is neonatal fc receptor blockers [moa]. Approved for neonatal fc receptor blocker [epc]. First approved in 2023.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VYVGART HYTRULO (efgartigimod alfa and hyaluronidase) is a neonatal Fc receptor (FcRn) blocker administered via subcutaneous injection approved in June 2023. It is indicated for myasthenia gravis, where it reduces pathogenic autoantibodies by blocking FcRn-mediated recycling of IgG antibodies. This formulation includes recombinant human hyaluronidase to enable subcutaneous delivery, improving patient convenience compared to the intravenous predecessor VYVGART. VYVGART HYTRULO represents an advancement in autoimmune disease treatment by offering improved accessibility and potentially better patient adherence.
$0.0BPart D
Mechanism of Action
Neonatal Fc Receptor Blockers
Pharmacologic Class:
Neonatal Fc Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG
Started Jan 2026
25 enrolled
Myasthenia Gravis Generalized
Why This Matters for Your Career
Worked on VYVGART HYTRULO at argenx? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.